Sellas Life Sciences saw a sharp decline in its shares following a shelf registration filing, which raised concerns about potential shareholder dilution. The stock dropped over 12% to €3.81, marking a nearly 10% decline for the week, despite maintaining a strong overall gain of over 250% in the past year. The company’s solid liquidity position and minimal debt are crucial for funding its costly clinical trials, like the pivotal Phase 3 study of their immunotherapy candidate, Galinpepimut-S (GPS), for acute myeloid leukemia. Investor focus will remain on the trial’s progress and the upcoming quarterly earnings report on May 19, 2026.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.ad-hoc-news.de/boerse/news/ueberblick/sellas-life-sciences-shares-retreat-on-capital-raising-prospect/69020767
